science wire

« BACK

Pharmacology



Results 1401 - 1450 of 1507.
« Previous 1 ... 25 26 27 28 29 30 ... 31 Next »


Pharmacology - Health - 23.12.2010
European Commission approves Novartis drug Tasigna for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
European Commission approves Novartis drug Tasigna for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia Pivotal Phase III data show superiority over standard of care Glivec in

Pharmacology - Health - 21.12.2010
Novartis drug Tasigna approved in Japan for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
Novartis drug Tasigna approved in Japan for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia Approval based on Phase III trial showing superiority of Tasigna to standard of car

Pharmacology - Health - 20.12.2010
Novartis investigational JAK inhibitor INC424 data met primary endpoint in Phase III trial of patients with myelofibrosis
Novartis investigational JAK inhibitor INC424 data met primary endpoint in Phase III trial of patients with myelofibrosis COMFORT-I trial shows INC424 provides significant clinical improvement in patients with myelofibrosis as measured by spleen size reduction High unmet medical need exists for patients with myelofibrosis, an uncommon and debilitating blood cancer Full results to be submitted for presentation at upcoming medical congress; worldw

Pharmacology - Health - 20.12.2010
Novartis affirms commitment to Russia through USD 500 million multi-year healthcare investment
Novartis affirms commitment to Russia through USD 500 million multi-year healthcare investment Novartis signs Memorandum of Understanding (MoU) with City of St. Petersburg for construction of

Health - Pharmacology - 16.12.2010
EMA/European Committee for Medicinal Products for Human Use (CHMP) update:
Basel, 16 December 2010 Roche provides update on Avastin for metastatic breast cancer following reviews in Europe and the United States Roche confirmed that following the reviews of Avastin (bevacizu

Business / Economics - Pharmacology - 15.12.2010
Novartis to become global leader in eye care, with agreement of 100% merger with Alcon
Novartis to become global leader in eye care, with agreement of 100% merger with Alcon Novartis Board of Directors unanimously approves merger for a value of USD 168 per Alcon share totaling USD 12&p

Health - Pharmacology - 09.12.2010
Study of Novartis drug Zometa for potential new use in early breast cancer did not meet primary endpoint in overall study population
Study of Novartis drug Zometa for potential new use in early breast cancer did not meet primary endpoint in overall study population Interim results of AZURE trial report Zometa added to standard adjuvant therapy did not show disease free survival advantage compared to standard therapy alone In subgroup of women with well-established menopause, an improvement in disease free survival and overall survival was shown in Zometa arm Current applicati

Health - Pharmacology - 09.12.2010
Novartis drug Afinitor plus hormonal therapy delays disease progression in advanced metastatic breast cancer patients
Study shows Novartis drug Afinitor plus hormonal therapy delays disease progression in advanced metastatic breast cancer patients Randomized Phase II study shows 61% of advanced breast cancer patients on everolimus plus tamoxifen had no tumor progression at six months vs.

Pharmacology - Health - 09.12.2010
Roche provides update on leading late-stage pharmaceutical pipeline
Basel and London, 9 December 2010 Roche provides update on leading late-stage pharmaceutical pipeline New data on medicines with the potential to redefine standard of care highlighted at Investor event Roche today will provide an update on its leading late-stage pipeline comprising twelve new molecular entities in key therapeutic areas.

Pharmacology - Health - 06.12.2010
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients LBH589 (panobinostat) shows sustained anticancer activity in Hodgkin lymphoma patients who relapse or are refractory after autologous stem cell transplant High unmet treatment need exists for patients who relapse or become refractory after initial treatment; patients are often in their mid-thirties or younger Bas

Pharmacology - Health - 06.12.2010
Longer-term Phase III data show Novartis drug Tasigna continues to surpass Glivec in slowing disease progression in patients with newly diagnosed CML
Longer-term Phase III data show Novartis drug Tasigna continues to surpass Glivec in slowing disease progression in patients with newly diagnosed CML Fewer patients taking Tasigna for Philadelphia ch

Pharmacology - Health - 04.12.2010
Phase III data published in Lancet show Novartis drug Zometa improves overall survival in newly diagnosed multiple myeloma patients
Phase III data published in Lancet show Novartis drug Zometa improves overall survival in newly diagnosed multiple myeloma patients This press release is not intended for United Kingdom news media Regimen including Zometa significantly improved both progression-free survival and overall survival when compared to regimen including oral clodronate Zometa provided significant clinical anticancer benefit independent of and in addition to significant

Health - Pharmacology - 01.12.2010
Data at ASH, SABCS demonstrate commitment of Novartis R&D in advancing treatments for patients with cancer and rare diseases
Data at ASH, SABCS demonstrate commitment of Novartis R&D in advancing treatments for patients with cancer and rare diseases 24-month update on Phase III data comparing Tasigna to Glivec in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase Afinitor plus hormonal therapy studied in patients with ER+/HER2- metastatic breast cancer with prior exposure to aromatase inhibitors Zometa studies continue to explore anticance

Pharmacology - Health - 11.11.2010
Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in early and late stage development
Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in early and late stage development Interim results from Phase III trial show ASA404 failed to meet primary endpoint of extending survival for the second-line treatment of non-small cell lung cancer Related impairment charges of approximately USD 120 million to be taken in fourth quarter 2010 Basel, November 11, 2010 - Novartis announced today that the

Health - Pharmacology - 04.11.2010
Potential for Novartis Meningitis B vaccine
New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate to cover majority of diverse meningococcal serogroup B strains Data show that antibodies induced by Novartis 4CMenB candidate killed 85 percent of a large collection of MenB strains in adults and 74 percent in infants , who are at highest risk for meningococcal disease Findings highlight the benefit of a multi-component MenB vaccine to provide broad coverage against div

Health - Pharmacology - 03.11.2010
Study shows drug Afinitor reduces size of SEGAs
Subependymal giant cell astrocytoma (SEGA) is a benign brain tumor found in children and adults with tuberous sclerosis (TS) that can cause severe brain swellin. These data previously reported at ASCO show nearly one-third of the 28 patients studied had a reduction of 50% or greater in the size of their largest SEGA.Additional study findings showed treatment with everolimus resulted in a clinically relevant reduction in overall frequency of seizures, which are associated with TS.

Pharmacology - Health - 03.11.2010
Onbrez Breezhaler from Novartis provides greater clinical benefits than tiotropium in new study of COPD patients
Onbrez Breezhaler from Novartis provides greater clinical benefits than tiotropium in new study of COPD patients Study shows Onbrez Breezhaler superior to tiotropium in reducing breathlessness and use of rescue medication and in improving overall health status INTENSITY is first blinded head-to-head study with primary goal of comparing once-daily Onbrez Breezhaler with tiotropium, an established COPD therapy Study shows once-daily Onbrez Breezha

Health - Pharmacology - 30.10.2010
Novartis drug Afinitor approved by FDA as first medication for children and adults with a benign brain tumor associated with tuberous sclerosis
Novartis drug Afinitor approved by FDA as first medication for children and adults with a benign brain tumor associated with tuberous sclerosis Subependymal giant cell astrocytoma (SEGA) is a benign

Health - Pharmacology - 25.10.2010
Phase III data show that Novartis meningococcal vaccine Menveo demonstrated robust immunogenicity in infants
Phase III data show that Novartis meningococcal vaccine Menveo demonstrated robust immunogenicity in infants New pivotal phase III data show Menveo induced immune responses in a high percentage of infants against four important meningococcal disease-causing serogroups The highest rates of meningococcal disease, a sudden, serious and often deadly disease, occur early in the first year of life Menveo has the potential to be the first meningococcal

Pharmacology - Health - 22.10.2010
Lucentis recommended for approval in EU
Novartis therapy Lucentis recommended for approval in EU to treat patients with vision loss due to Diabetic Macular Edema, a serious complication of diabetes CHMP positive opinion supports Lucentis approval in EU for treatment in patients with visual impairment due to diabetic macular edema (DME) Pivotal data shows Lucentis provided rapid, superior and sustained vision gains compared to the current standard of care Diabetes-associated eye diseas

Health - Pharmacology - 22.10.2010
Novartis Phase III study indicates MF59 adjuvanted influenza vaccine, Fluad , is 75 percent more efficacious than studied non-adjuvanted vaccines in young children
Novartis Phase III study indicates MF59 adjuvanted influenza vaccine, Fluad , is 75 percent more efficacious than studied non-adjuvanted vaccines in young children Phase III results demonstrate 89 percent efficacy of Fluad (vs.

Pharmacology - Health - 16.10.2010
Long-term data show Novartis once-yearly Aclasta preserves bone mass and provides fracture protection in postmenopausal osteoporosis
Long-term data show Novartis once-yearly Aclasta preserves bone mass and provides fracture protection in postmenopausal osteoporosis Aclasta reduced the risk of new spine fractures by 52% over six years versus patients who stopped treatment after three years New data from six-year study validate Aclasta safety profile and support long-term use of annual infusions in patients with postmenopausal osteoporosis More than one million Aclasta infusion

Pharmacology - Health - 12.10.2010
Novartis affirms commitment to sustain efforts toward final elimination of leprosy in partnership with World Health Organization
Novartis affirms commitment to sustain efforts toward final elimination of leprosy in partnership with World Health Organization Novartis signs Memorandum of Understanding with the World Health Org

Health - Pharmacology - 11.10.2010
Phase III Novartis data show potential benefit of Afinitor plus Sandostatin LAR in patients with advanced neuroendocrine tumors
Phase III Novartis data show potential benefit of Afinitor plus Sandostatin LAR in patients with advanced neuroendocrine tumors Everolimus plus octreotide LAR extended time without tumor growth from

Pharmacology - Health - 05.10.2010
Novartis discontinues development of two investigational compounds reflecting enhanced focus on portfolio prioritization and productivity
Novartis discontinues development of two investigational compounds reflecting enhanced focus on portfolio prioritization and productivity Human Genome Sciences and Novartis to stop further developmen

Pharmacology - Business / Economics - 30.09.2010
Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, reaches settlement agreement with US Attorney’s Office
Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, reaches settlement agreement with US Attorney's Office Novartis Pharmaceuticals Corporation reaches resolution with US Attorney's

Health - Pharmacology - 24.09.2010
Novartis drug Tasigna recommended for approval in European Union to treat patients with newly diagnosed Ph+ chronic myeloid leukemia
Novartis drug Tasigna recommended for approval in European Union to treat patients with newly diagnosed Ph+ chronic myeloid leukemia Positive CHMP opinion based on pivotal trial showing Tasigna super

Health - Pharmacology - 24.09.2010
Novartis receives EU approval recommendation for TOBI Podhaler , a fast and simple therapy that helps reduce treatment burden for cystic fibrosis patients
Novartis receives EU approval recommendation for TOBI Podhaler , a fast and simple therapy that helps reduce treatment burden for cystic fibrosis patients CHMP supports approval of TOBI Podhaler, a new dry powder form of tobramycin for treating chronic P. aeruginosa lung infection in cystic fibrosis patients over six Data show new formulation reduces administration time by 72% compared to TOBI, with same efficacy and using more convenient

Health - Pharmacology - 22.09.2010
Novartis gains FDA approval for a novel multiple sclerosis treatment
Novartis gains FDA approval for a novel multiple sclerosis treatment
Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression Gilenya is the first approved oral treatment indicated for relapsing forms of MS in the US, a major advance for people with this disease.

Health - Pharmacology - 22.09.2010
Novartis drug SOM230 is first medical therapy to show efficacy in a Phase III trial in Cushing’s disease, a debilitating hormonal disorder
Novartis drug SOM230 is first medical therapy to show efficacy in a Phase III trial in Cushing's disease, a debilitating hormonal disorder SOM230 reduced urinary free cortisol (UFC) levels in majority of patients; 26% of patients randomized to SOM230 900g achieved normal UFC levels With reduced UFC levels, clinical symptoms improved including lower blood pressure, total cholesterol and weight loss Cushing's disease is caused by a pituitary tumo

Pharmacology - Health - 19.09.2010
Onbrez Breezhaler is superior to salmeterol in reducing breathlessness for patients with COPD
Novartis study shows Onbrez Breezhaler is superior to salmeterol in reducing breathlessness for patients with COPD Phase III INSIST study shows once-daily Onbrez Breezhaler gave better 24-hour bronchodilation than twice-daily salmeterol , a current mainstay of treatment Data show Onbrez Breezhaler significantly reduced use of rescue medication in patients with chronic obstructive pulmonary disease (COPD) New results provide further evidence that

Pharmacology - Health - 15.09.2010
Novartis JAK inhibitor provides marked and durable clinical benefits in patients with myelofibrosis, a rare, life-threatening blood cancer
Novartis JAK inhibitor provides marked and durable clinical benefits in patients with myelofibrosis, a rare, life-threatening blood cancer Myelofibrosis is a blood cancer characterized by bone marrow failure, enlarged spleen, poor quality of life and shortened survival Phase I/II data published in NEJM demonstrate clinical benefits of JAK1 and JAK2 inhibitor INC424, including reduction of spleen size and alleviation of debilitating symptoms Nova

Health - Pharmacology - 12.09.2010
Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease
Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease Pivotal data show that the large majority of infants vaccinated with N

Pharmacology - Health - 03.09.2010
Novel antimalarial drug candidate
Novartis announced today that scientists at the Novartis Institute for Tropical Diseases (NITD), in collaboration with researchers from the Genomics Institute of the Novartis Research Foundation (GNF), the Swiss Tropical and Public Health Institute and The Scripps Research Institute have discovered a novel compound that shows promise as a next generation treatment for drug resistant malaria.

Pharmacology - Health - 27.08.2010
Novartis drug Tasigna approved in Switzerland after fast-track review for treatment of patients with newly diagnosed Ph+ CML
Novartis drug Tasigna approved in Switzerland after fast-track review for treatment of patients with newly diagnosed Ph+ CML Pivotal Phase III trial data demonstrate superiority to standard of care G

Health - Pharmacology - 23.08.2010

Pharmacology - 23.07.2010
Sandoz leads the way with first generic version of ’gold standard’ anti-thrombotic Lovenox [1]
Sandoz leads the way with first generic version of 'gold standard' anti-thrombotic Lovenox Sandoz is the first company to receive US approval to market a more affordable generic version of the leadin

Pharmacology - 20.07.2010
Novartis receives approval in China for Rasilez, a first-in-class direct renin inhibitor for high blood pressure, the leading preventable cause of death in China
Novartis receives approval in China for Rasilez, a first-in-class direct renin inhibitor for high blood pressure, the leading preventable cause of death in China Rasilez provides significant blood pr

Pharmacology - 14.07.2010
Plaintiffs and Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, agree to resolve all gender discrimination claims associated with class action
Plaintiffs and Novartis Pharmaceuticals Corporation, a US subsidiary of Novartis AG, agree to resolve all gender discrimination claims associated with class action Agreement reached between Novarti

Pharmacology - 01.07.2010
Phase III study shows Novartis drug Afinitor more than doubles time without tumor growth in advanced pancreatic NET patients
Phase III study shows Novartis drug Afinitor more than doubles time without tumor growth in advanced pancreatic NET patients Everolimus extended median progression-free survival from 4.6 to 11.0 months vs.

Pharmacology - 18.06.2010
FDA approves Tasigna for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Glivec
FDA approves Tasigna for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Glivec In head-to-head trial, Tasigna reduced leukemia-causing protein faster than Glivec, resulting in lower rates of cancer progression even as early as 12 months Regulatory submissions under way worldwide, with applications currently filed in the EU, Switzerland and Japan Basel, June 17, 2010 - Following a priority review, the US Fo

Pharmacology - 18.06.2010
New Phase II study in gout patients shows Novartis ACZ885 prevented acute flares better than standard anti-inflammatory therapy
New Phase II study in gout patients shows Novartis ACZ885 prevented acute flares better than standard anti-inflammatory therapy ACZ885 significantly reduced rate of acute flares up to 75% vs.

Pharmacology - 11.06.2010
FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS
FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS Committee voted in favor of approval of FTY720 (fingolimod), as treatment in relapsing remitting multiple sclerosis, affirming the drug's positive benefit/risk profile FTY720, potentially first in a new class of MS therapy, represents a significant advance as an efficacious oral treatment for people with relapsing r

Pharmacology - 05.06.2010
Study at ASCO shows Novartis drug Afinitor first to shrink SEGA brain tumors in children and adults with tuberous sclerosis
Study at ASCO shows Novartis drug Afinitor first to shrink SEGA brain tumors in children and adults with tuberous sclerosis Phase II study shows meaningful reduction in brain tumor size in 75% of patients with subependymal giant cell astrocytomas (SEGAs) from baseline to six months SEGAs are benign brain tumors associated with tuberous sclerosis (TS) that primarily affect children and adolescents and can cause severe brain swelling No patient de

Pharmacology - 05.06.2010
Adding Novartis drug Zometa to chemotherapy significantly improved overall survival in study of newly diagnosed multiple myeloma patients
View all media releases June 05, 2010 14:15 CET Adding Novartis drug Zometa to chemotherapy significantly improved overall survival in study of newly diagnosed multiple myeloma patients This press release is not intended for United Kingdom news media Phase III data show Zometa, a bone-targeted agent, provided significant clinical anticancer benefit and significantly reduced risk of skeletal-related events Survival advantage observed with Zometa
« Previous 1 ... 25 26 27 28 29 30 ... 31 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |